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Abstract 
Corticosteroids are hormones involved in many physiological responses such as 
stress, immune modulation, protein catabolism and water homeostasis. The 
subfamily of glucocorticoids are used systemically in the treatment of inflammatory 
diseases or allergic reactions. In the eye, glucocorticoides are used to treat macular 
oedema, inflammation and neovascularization. The most commonly used 
glucocorticoid is Triamcinolone acetonide (TA). The pharmaceutical formulation of 
TA is not adapted for intravitreal administration but has been selected by 
ophthalmologists because its very low intraocular solubility provides sustained effect.  
Visual benefits of intraocular TA do not clearly correlate with morpho-anatomical 
improvements, suggesting potential toxicity. We therefore studied, non common, but 
deleterious effects of glucocorticoids on the retina. We found that the intravitreal 
administration of TA is beneficial in the treatment of neovascularization because it 
triggers cell death of endothelial cells of neovessels by a caspase independent 
mechanism. However, this treatment is toxic for the retina because it induces a non-
apoptotic, caspase independent cell death related to paraptosis, mostly in the retinal 
pigmented epithelium cells and the Müller cells.  
 
Keywords: retina, glucocorticoids, non apoptotic cell death, caspase-independent 
cell death, intravitreal administration 
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1. Corticosteroids 
Corticosteroids are hormones produced in the adrenal cortex. They are involved in 
many physiological responses such as stress, immune modulation, protein 
catabolism and water homeostasis. This hormone family comprises two subfamilies: 
mineralocorticoids, involved mostly in electrolyte control and glucocorticoids 
controlling  fat, protein and carbohydrate metabolism.  
Therapeutically, glucocorticoids are used systemically in the treatment of 
inflammatory diseases like arthritis, asthma and allergic reactions. They are also 
administered topically to the skin, nose or lungs [1]. 
 
2. The use of glucocorticoids in the eye 
The retina is a neural tissue lining in the inner surface of the eye. In humans and 
other vertebrates the retina is composed of three layers of nerve cell bodies and two 
layers of synapses (fig 1A). The outer nuclear layer contains the photoreceptors, 
which are the main light sensitive cells of the retina. Two types of photoreceptors are 
found: the rods and the cones. Rods provide black-and-white vision, while cones are 
responsible for the perception of colour. The inner nuclear layer contains bipolar, 
horizontal and amacrine cells, while the ganglion cell layer contains essentially the 
ganglion cells. These neural layers are separated by two layers of synaptic contacts, 
the so called outer and inner plexiform layers (OPL and IPL respectively) (figure 1A).  
The neural impulse, originating in the photoreceptors, undergoes complex 
processing by the neurons of the inner nuclear layer and exits the retina though the 
ganglion cells whose axons form the optic nerve. In the eyes of humans and other 
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primates, the retina has an area where cones are most concentrated, the macula 
lutea. The macula represents 2-3% of the surface of the retina but is responsible for 
90% of the information coming out of the retina. A small depression is seen in the 
center of the macula, known as fovea, where only cones are found. This is the area 
of maximal visual acuity (figure 1B). 
In order to avoid diffraction of photons by blood cells, the fovea does not contain 
blood vessels. In addition, the homeostasis of fluids in this region is critical for its 
proper function. These characteristics are altered in several retinal diseases. For 
example, an increase in water content in the macula, called macular edema, is one 
of the leading causes of blindness in diabetic retinopathy. The unbalance between 
fluid entry and exit in the retina results in increased retinal thickness, intra retinal 
cysts and sub retinal fluid, forming a cystoid macular edema (Figure 1C). Moreover, 
a person with macular edema is likely to have blurred vision, leading to social 
blindness (no recognition of faces, inability to read). In the proliferative forms of 
diabetic retinopathy (less common since laser photocoagulation has become widely 
used in industrialized countries), new blood vessels form at the surface of the retina. 
These new vessels can bleed and induce tractional retinal detachments, ultimately 
causing total blindness without active treatment. 
Intravitreal administration of glucocorticoids is a very commonly practiced treatment 
for macular edema and less commonly for some forms of neovascularisation [2]. The 
most frequently used corticoid is Triamcinolone acetonide (TA). This specific 
corticosteroid formulation, not adapted and not originally indicated for the eye, has 
been selected by ophthalmologists because of its sustained effect, due to its very 
low intraocular solubility.  The effect of the intravitreal injection of TA is impressive in 
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some aspects. For instance, a single administration results in a dramatic decrease in 
macular edema. Figure 1 C and D shows OCT images of the same eye before and 1 
week after injection. This effect begins to be noticed already one hour after the 
treatment. When used for the treatment of choroidal neovascularizations associated 
with Age-related Macular Degeneration (AMD), for example, TA decreases the 
vascular leakage in the short-term. The vascular effects of TA have been confirmed 
in animal models of choroidal and retinal neovascularization [3].  
In spite of these positive effects of TA on retinal anatomy, the improvement of long 
term visual acuity is observed in only 50% of patients treated for macular edema [4]. 
When associated with other anti vascular drugs for the treatment of neovascular 
AMD, severe side effects have been reported [5].  
In addition, the safety of TA is still a subject of controversies. In particular, it is not 
clear whether the observed toxicity results from the glucocorticoids themselves 
(including TA) or is a consequence of the use of specific vehicles . This led us to 
investigate the toxicity of glucocorticoids in the retina, with a particular emphasis on 
TA.  
 
 
3. The toxicity of TA in the retina  
Previous research has allowed the toxicity of TA in non ocular tissues to be 
minimized. However, the toxic effect of TA is a fact and has been initially reported 
after administration to chick embryo where it is responsible for lymphocyte toxicity 
and malformations [6]. Several authors have also performed studies on TA toxicity in 
the retina. A non exhaustive list is shown in Table 1. Overall, this table indicates that 
the results are inconclusive, spanning from toxic to non toxic effects for TA, or 
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pointing to the toxic effects of preservative used in the pharmaceutical preparations. 
One of the most limiting points of these studies is that no mechanism of cell death 
could be identified, thus questioning the suspected toxicity of TA.  
A similar situation can be seen concerning the control of neovascularization with this 
drug. TA has been shown to down regulate the expression of tumour necrosis factor 
α, vascular endothelial growth factor (VEGF), interleukin 1, and matrix 
metalloproteinases, all of them influencing neovascularization [7, 8]. TA has also 
been reported to have an anti-proliferative effect on endothelial cells [9, 10].  So far, 
the antiangiogenic/angiostatic activity of corticosteroids results from a combination of 
factors. It remains however unknown if TA can directly induce vascular endothelial 
cell death.  
 
3.1 The mechanisms of cell death 
During most pathological processes cell death is essentially carried out 
through either passive or active mechanisms. Passive mechanisms are involved in 
extreme cell injury and end up into the release of the entire cell contents in the 
tissue. This process of cell death is called necrosis. By contrast, the cells suffering 
from mild or light injury die through an active and programmed cell death [11] that 
will protect the neighbouring cells from extensive damage. Caspase-dependent 
apoptosis is the most widely studied and characterized pathway of programmed cell 
death (for a review see [12]). However, other forms of active cell death are now 
recognized and their role in tissue homeostasis and pathology is being unveiled [13-
15]. Thus, other apoptotic caspase-independent mechanisms (also called apoptotsis-
like mechanisms) have been described. Caspase-independent cell death 
mechanisms result from the activation of other proteases such as calpains [16] 
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cathepsins [17, 18] or serine proteases [19, 20] that in turn activate other effectors of 
cell death such as Apoptosis-Inducing Factor, AIF [21] or L-DNase II [22, 23]. In 
recent years other processes have been considered as involved in mechanisms of 
cell death. Autophagy, for instance, is an evolutionarily conserved mechanism 
allowing the elimination of unnecessary or damaged organelles and the recycling of 
their proteins. In neural cells, autophagy is essential for cell survival, but when over 
activated may lead to cell death [24, 25]. Recently, an additional cell death program, 
initiated in the cytoplasm and named paraptosis, has been characterized [13]. This 
type of cell death has been first described after the activation of the insulin-like 
growth factor receptor [26-28].  A similar death phenotype is initiated after the 
activation of neurokinin-1 receptor by its ligand, substance-P[29]. These types of cell 
death are insensitive to broad-range caspase inhibitors and present an extensive 
cytoplasmic vacuolization [29, 30]. Paraptosis also involves the activation of MAP 
kinases and can specifically be blocked by AIP-1/Alix [13]. This last characteristic is, 
up to now, the only functional evidence that allows this type of cell death to be 
identified.  
 
3.2 TA induces cell death in endothelial cells and neovessels 
We have recently shown that TA strongly affects endothelial cell viability when 
assayed on bovine retinal endothelial cells (BREC) [31]. In these experiments, the 
percentage of living cells was reduced to almost 50% after exposure to TA for 24 
hours at a concentration of 1 mg/ml, which is the concentration normally used in 
human clinics. The rate of survival was further reduced as exposure time increased. 
This effect was similar regardless of whether confluent or non-confluent cells were 
used, suggesting that proliferation is not a major process controlling the size of the 
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9 
studied cell population. However, this does not mean that proliferation is not 
affected. Indeed,, the evaluation of the rate of DNA synthesis using BrdU 
incorporation revealed a reduced proliferation [31]. However, the effects on 
proliferation could not explain the magnitude of cell loss quantitatively. To test the 
hypothesis that cell death is contributing to the observed, TA-induced cell loss, we 
first measured the amount of free lactate dehydrogenase (LDH) in the culture 
medium. This enzyme was used as a marker of passive cell death by necrosis. We 
found that necrosis-related LDH release was increased. However, a decrease in the 
size of the cell population through the combined decrease of proliferation and 
increased necrosis could still not entirely explain the magnitude of the observed cell 
loss. Taken together, this evidence suggests that additional mechanism of cell death, 
via active pathways, are also involved. Indeed, our experiments showed that these 
cells expose phosphatidyl serine on the outer side of the plasma membrane, as 
revealed by annexin V binding. However, neither activation of the central caspase of 
the classic apoptotic pathway, caspase 3, nor TUNEL labelling (indicating a 
degradation of DNA in the nucleus) were seen. These results suggest that the 
classic apoptotic pathway of cell death is not activated. 
The presence of cell death in TUNEL negative cells may be explained by either a 
lack of DNA degradation or by a degradation of DNA which can not be labelled with 
this technique. This happens for instance when L-DNase II, an enzyme activated by 
serine proteases, produces 3’P ends which can not be labelled by the terminal 
transferase, enzyme used in TUNEL assays. It is worth noting that terminal 
transferase can only add nucleotides to 3’OH ends. Consistently, L-DNase II, an acid 
endonuclease, cleaves DNA and releases 3’P ends that can not be labelled by the 
TUNEL technique. In our experiments, LEI/L-DNase II was associated with apoptosis 
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10 
of BRECs after 72 h of TA exposure (figure 2). This explains why these cells, 
displaying apoptotic morphology and Annexin V staining, but yet remain TUNEL 
negative. In addition, as TUNEL is the commun technique used to assay the 
induction of cell death in a tissue, many dying cells remain unrevealed. In addition to 
LEI/L-DNase II-induced cell death where L-DNase II is translocated to the nucleus 
upon its activation by serine proteases, AIF is also targeted to the nucleus (fig 2). 
Interestingly, it has to be stressed that AIF is translocated to the nucleus only after L-
DNase II.  Indeed,, double immunolabelling of these two effectors of apoptosis 
showed that cells can display activated L-DNase II without nuclear translocation of 
AIF. The opposite was never seen, suggesting that AIF is involved in this cell death 
only at later stages.  
According to these data, activation of a caspase-independent apoptosis-like cell 
death is responsible for the death of endothelial cells. Previous studies performed in 
our laboratory showed a decrease in neovascularization after treatment with TA in an 
induced model of choroidal neovascularization [32]. To induce the growth of 
neovessels C57/B6 mice were exposed to an Argon laser at 400mW, a procedure 
that burns the retina and destroys the pigmented epithelium in a reduced area 
(50µm). 2 weeks after this treatment, the eyes were injected intravitreally with TA. 
The effects were evaluated 1 month later. Figure 3 shows a burned retinal area 
where, the vessels are labelled with CD31. The neovessels that are growing in a 
normally avascular area are shown by an arrow. It can be seen that after TA 
treatment the nuclei of the endothelial cells of these vessels are fragmented and 
labelled with anti-LDNase II, a feature not seen in control eyes burned but  not 
treated wih TA. This suggests that in vivo TA has the same effect on endothelial cells  
as in vitro. 
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Taken together these data indicate that TA relieves neovascularization by 
decreasing proliferation and inducing caspase-independent cell death of endothelial 
cells. This represents a potentially beneficial effect in the treatment of 
neovascularization. The question which remains to be answered is then: is TA safe 
for the retina? 
 
3.3 The retinal toxicity of TA: 
In order to investigate the effects of TA on the rat retina, we injected TA into the 
vitreous of rat eyes [33]. While the control eye, injected with a saline solution, 
showed no abnormalities (figure 4), the eyes receiving TA showed marked 
morphological changes 8 days after injection mostly in in RPE (retinal pigmented 
epithelial cells) cells  (figure 4). The photoreceptors outer segments were 
disorganized but the cell bodies were preserved. The RPE layer was not interrupted 
but the individual cells were enlarged and presented cytoplasmic vacuoles and 
increased microvilli, a morphology suggesting a replacement of lost RPE cells by 
enlargement of the neighbouring cells. These modifications were confirmed by 
electron microscopy (figure 4). The cells of the RPE were not the only cells modified. 
Vacuolization within the cytoplasm was also observed in Müller cells. In these cells, 
the vacuoles were essentially seen in their prolongations at the outer nuclear layer 
level. These morphological changes suggested a cellular stress but they were not in 
accordance with an apoptotic cell death. Moreover, immunostaining of cryosections 
of these retinas with anti-activated caspase 3 and TUNEL assays were negative. No 
nuclear translocation of L-DNase II or AIF was found suggesting the absence of their 
activation [33]. In order to explore the effects of TA on these cells, we investigated its 
actions in vitro in cultured RPE and Müller cells. It is interesting to note that the 
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12 
morphological effects observed in vitro were similar to those seen in vivo. Figure 5 
shows the electronic micrography of a cultured RPE cell where the presence of 
vacuoles is also induced by TA. In cultured cells TA induced a dose-dependent 
reduction in cell viability of both cell types with the loss of about 50% of living cells at 
0.1 mg/ml concentration, indicating that TA was highly toxic for these cells. However, 
as observed with retinal sections, no TUNEL positive cells could be detected (figure 
6). In addition, annexin-V did not bind to cells exposed to TA. Other biochemical 
markers of apoptosis, such as activation of caspase-3 and release of cytochome C 
from the mitochondria, were also negative. These data excluded caspase-dependent 
apoptosis as a potential mechanism for the observed cell death induced by TA. Two 
markers of caspase-independent apoptosis (L-DNase II and AIF) were further 
investigated and their activation was also not detected (figure 6).  The morphological 
modifications observed in these cells are indicative of different types of cell death: 
necrosis, autophagy and paraptosis. To investigate the possible involvement of a 
passive cell death,  i.e. necrosis, we measured the LDH cell release. Only cells 
exposed to very high concentrations of TA, inducing the formation of crystals, 
triggered necrosis. In the absence of crystals, this type of cell death was not induced.  
Autophagic activity was investigated by using both monodansylcadaverine (a 
compound staining acidic vesicles) and anti-LC3, an antibody staining mature 
autophagic vacuoles [33]. Only some of the vacuoles were stained with 
monodansylcadaverine in TA-treated RPE cells. Most importantly, MAP-LC3 
labelling was not significantly different in TA treated and control cells, indicating that 
autophagy is not activated. We finally, decided to explore the possible involvement of 
paraptosis.  
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Several cues were in favour of the activation of paraptosis in TA treated cells: the 
observed cell death occurs with no DNA condensation, no formation of apoptotic 
bodies, no caspases activity and no DNA degradation. However, extensive 
cytoplasmic vacuolization is seen. In order to test this hypothesis, we over-
expressed AIP-1/ Alix in these cells. As shown in Figure 7, over-expression of AIP-
1/Alix in wild type significantly reduced TA-induced toxicity. This protection is lost if 
only the C-terminal part of the protein is expressed.  
Taken together these data indicate that when exposed to TA, RPE and RMG cells 
die by paraptosis, a non-classical form of cell death. 
 
4. The use of glucocoticosteroids in the eye revisited 
Contradictory observations and discrepancies regarding the clinical safety of 
intravitreous TA toxicity have been published [34-36], depending mostly on the 
techniques used to detect toxicity. In the rat eye, using electron microscopy we could 
detect clear lesions in RPE and in Müller cells 8 days after injection of TA. However, 
all currently used immunohistochemical markers for apoptosis or autophagy 
(activated caspase-3, TUNEL assay, and MAP-LCA) are negative. This may explain 
why other authors previously failed to clearly detect any cell death even when toxicity 
markers have been observed. Previous in vitro experiments have also shown that 
direct incubation of cells with crystalline TA induces activation of caspases and 
stress proteins [37, 38].  This effect was lost when the crystals were separated from 
the cells by a microporous membrane [39]. However, in these experiments, other 
potential mechanisms of cell death were not explored. It is interesting to note that 
this situation does not seem to be exclusive for the retina, but might also explain the 
“absence” of cell death in various brain regions reported in some neurodegenerative 
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pathologies [40, 41] where, as in the retina, no classical apoptosis markers could be 
detected. The involvement of non-classical cell death effectors, similar to that 
discussed in this report, should be performed in the relevant paradigms of 
neurodegenerative pathologies occurring in the absence of the classical apoptosis.  
The cell death induced by TA is related to paraptosis. It is worth noting that 
paraptosis takes place during cell differentiation in the development of the nervous 
system as well as in some cases of neurodegeneration [42]. This indicates that the 
investigation of different cell death mechanisms is critically important in evaluating 
the toxicity of a product or even its therapeutic efficacy. This is clearly the case for 
the anti-vascular activity of steroids.  
Glucocorticoids were known from a long time to induce vascular effects. Actually, the 
McKenzie test, based on skin bleaching [43, 44], has been used to establish the 
classification of glucocorticoid potency and cutaneous absorption. This test uses the 
visual quantification of the skin whitening after 8 to 48 h of exposure to different 
glucocorticoids applied topically under occlusion. Although this test is widely used, 
the exact mechanism of skin whitening remains unknown . The effects of steroids on 
growing vessels have been described in a seminal paper by Folkman and Ingber 
[45]. These authors showed that dexamethasone or hydrocortisone induces the 
regression of neovessels in the chorioallantoid membrane. They have demonstrated 
that the vascular action of these drugs is related to their effect on the basal 
membrane of growing vessels. Further studies have shown that steroids inhibit the 
proliferation of human endothelial cells [46]. In our work we showed a decrease of 
proliferation but also an induction of cell death. Here again, classical mechanisms of 
cell death, caspases-dependent apoptosis or necrosis, are not activated and the use 
of the classical TUNEL technique cannot accurately reveal dying cells. Moreover, TA 
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has also been shown to induce vascular changes, at the level of the choroids [47-49] 
in normal eyes.The potential toxic effect of TA on resting versus proliferating 
choroidal neovessels is currently under investigation.  
Glucocorticosteroids are frequently used in a systemic way and injected 
intravenously. Our results raise the question of the effect of these bolus injections on 
vasculature. Endothelial cell damage has been reported in veins of rabbits treated 
with methylprednisolone. This observation is in agreement with the superficial skin 
ecchymoses frequently seen after long-term corticotherapy [50]. Also the question of 
the effects of corticosteroids on other endothelia of the microcirculation  has to be 
addressed. In our experiments, we found a relatively selective effect of TA on the 
choriocapillaries as compared to the retinal vasculature. In fact, these two types of 
capillaries are quite different. Choriocapillary endothelium is fenestrated and much 
less protected than retinal capillaries, which are surrounded by pericytes, astrocytes, 
and retinal Müller glial cells. Moreover, TA could also exert an indirect effect through 
the downregulation of COX2 in RPE cells [31]. This evidence points to the fact that 
the results obtained on one type of these two capillaries cannot obviously be 
extrapolated to the other one. The deleterious effects of chronic use of 
glucocorticoids have been described in other systems. For instance, the long-term 
use of topical steroids on the skin is often accompanied by severe and often 
irreversible effects as skin atrophy [51]. This is also the case for the muscle, where 
the use of glucocorticoids is a common cause of muscle atrophy [52]. Whether these 
tissues are also suffering cell death by non canonical mechanisms is not know. This 
issue is critical in the evaluation of the safe use of theses valuables drugs and will be 
matter of a future investigation. 
 
Page 16 of 36
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
5. Conclusion 
Our work shows for the first time that glucocorticoids limit neovacularization by 
inducing cell death in endothelial cells. We also demonstrate a direct retinal toxicity 
of glucocorticoids. In both cases, the activated cell death mechanism  is caspase 
independent, therefore undetectable when using techniques that detect this form of 
cell death. Taking into account that caspase-independent cell death may occur 
without any macroscopic reaction, in the long term, such cell death may remain 
undetectable in the routine clinical practice and promote deleterious consequences 
on visual acuity. 
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Captions to figures: 
 
 Figure 1 : Anatomy of the retina and macular edema : Panel A: Cross section of a rat 
retina stained with Toluidine Blue. The different cellular layers of the retina are shown: 
GCL: ganglion cell layer, INL: Inner nuclear layer, which contains the bodies of bipolar 
cells, Müller cells and intermediate cells. ONL: outer nuclear layer, containing the 
photoreceptor cell bodies, RPE: retinal pigmented epithelium cells. RIS: Rod inner 
segments, ROS: Rod outer segments.  Panel B: Fovea and macula. The upper panel 
shows an eye fundus. On the left there is  the optic nerve (ON) and the normal retinal 
vascularization. In the a darker, avascular, area can be seen: the macula. In the center 
of this area a depression is found: the fovea, the region of highest visual acuity. The 
lower panel shows a cross section of the fovea. The different cell layers are pushed to 
the side and the photoreceptors are directly exposed to light. Panel C:  Optical 
coherence tomography (OCT) scan of a diabetic patient before triamcinolone 
acetonide (TA) injection and in panel D, 1 week after TA administration. Printed with 
permission from Miyamoto et al Ophthalmology Volume 113, Issue 11, November 
2006, Pages 2048-2053. Elsevier Copyright 2006 
 
Figure 2 : AIF and L-DNase II activation in TA treated BRECs. 
 Right panel:  Apoptosis inducing factor (AIF) immuno-labeling was performed in 
control cells treated with the TA vehicle (1% ethanol), wherecytoplasmic labeling can 
be seen. This is also the case in cells treated with 0.1 mg/ml TA for 3 days. After 5 
days of TA treatment, cells with condensed nuclei (arrows) show nuclear staining for 
AIF. Nuclei were identified by DAPI staining. Left panel: L-DNase II activation in TA 
treated BRECs. LEI/L-DNase II immuno-labeling was performed in control cells as 
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before and cytoplasmic labelling is seen. Cells treated with 0.1 mg/ml TA for 3 or 5 
days havecondensed nuclei (arrows) and present nuclear staining of LEI/L-DNase II, 
indicating L-DNase II activation. Reproduced with permission from Molecular Vision 
2009; 15:2634-2648. 
 
Figure 3 : TA effects on neovessels in vivo : 10-12 week old C57/bk6 mice were 
treated with an argon laser of 50µ, 400mW, 0.05 sec (burning rate 0.40.  2 weeks after 
burning), 15µg of TA was injected in the eye (panels A to F) or a saline solution was 
used for control animals (panels G to J). Mice were sacrificed using CO2 1 month 
later. The eyes were cryosectionned and immunostained with DAPI (panel A and G) to 
identify nuclei, anti-LEI/L-DNase II (panel B and H) and anti CD31 (panel C and I), 
which identifies endothelial cells. Panel D and J depict the merged  images. 
Neovessels are present in the outer nuclear layer, a zone that is normally avascular 
(white arrows on panel C and I). Panel E and F are higher magnifications of the red 
square areas. The chromatin in the endothelial cells is disrupted and a clear nuclear 
labelling of L-DNase II is seen. Scale bar represents 50µm. 
 
Figure 4: Structural alterations of the rat retina 8 days after intravitreous injection of 
TA. A: Retina from a PBS-treated rat (control). B: Retina from TA-injected eyes. Black 
arrows show vacuoles and enlarged retinal pigment epithelium (RPE) cells. Scale bar 
represents 10µm. Lower panels are ultrathin sections. D: Retina from a PBS-treated 
rat (control). E: Retina from TA-injected eyes. Panels  C and F are higher 
magnifications of degraded mitochondria ( F arrows). C: Vacuoles (arrows) are also 
observed in retina glial Müller cells prolongations. Note preservation of photoreceptor 
nuclei. ROS indicates rod outer segments, RIS indicates inner segments. RPE 
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indicates retinal pigmented epithelial cells. Reproduced with permission from 
Molecular Vision 2007; 13:1746-57. 
 
Figure 5: Transmission electron microscopy observations of TA-treated ARPE 19 
cells. A: Control ARPE 19 cells. B and C: ARPE-19 cells TA-treated with 0.1 mg/ml 
(B) and 1 mg/ml TA (C), showing membrane limited (arrows) or unlimited vesicles and 
dilated endoplasmic reticulum (arrowhead). In panel C, a more advanced stage of 
degeneration is represented. Reproduced with permission from Molecular Vision 
2007; 13:1746-57. 
 
Figure 6. The cell death activated in ARPE19 is caspase-independent. A: 
Subconfluent ARPE 19 cells were incubated for 72 h in the presence 0.1 mg/ml 
triamcinolone. Protein extracts were separated in 4-10% PAGE, transferred to 
nitrocellulose and revealed with anti-caspase 3. No activation of caspase 3 is seen in 
TA-treated cells. Apoptosis induced in HL-
used as positive control. B: Triamcinolone-treated or control ARPE 19 cells were 
stained with DAPI or immunostained with anti-AIF (red) or anti LEI/L-DNase II (green). 
No nuclear translocation of these apoptosis markers was seen, neither in cells with 
normal morphology, nor in cells with an altered nuclear morphology . Reproduced with 
permission from Molecular Vision 2007; 13:1746-57. 
 
 
Figure 7: Paraptosis in TA treated-ARPE-19 cells. A: Effect of Alix overexpression on 
TA induced cell death. ARPE 19 cells were nucleofected with Alix-WT or with its C-
terminal moiety. Controls were run with untransfected cells or in cells transfected with 
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the PCI empty vector. 48 h after transfection cells were treated with TA and cell 
survival was measured with the 3-(4,5-dimethylthiazol-2- yl)-2,5 phenyltetrazolium 
bromide test method. Alix-CT has no effect on cell survival but Alix-WT protects cells 
form death. * indicates a p<0.05 . Reproduced with permission from Molecular Vision 
2007; 13:1746-57. 
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 Table 1 : Retinal toxicity of TA In vivo  
 IVT= intravitreal administration, ERG = electroretinogramme, OCT = optical coherence tomography 
       
 
 
Experimental 
settings 
Injection length Analysis  Results and conclusions 
 
McCuen et 
al. 1981[50] 
IVT rabbit 
eye fundus 
intraocular 
pressure 
Histology 
TA1mg/NaCl 3 months Slit lamp 
optical and electronic 
microscopy  
ERG 
No toxicity  
 
Hida et al.  
1986 [40] 
IVT rabbit  
eye fundus  
Histology 
Vehicles of 
Kenacort 
2 weeks Slit lamp 
optical microscopy 
Benzyl alcohol toxicity  
 
Kilvilcim et 
al. 2000 [51]  
IVT rabbit ( after 
vitrectomy 
1, 2 ou 4 mg 
TA 
140 days Slit lamp 
optical and electronic 
No toxicity 
Table
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+silicone) 
 eye fundus  
Histology 
orKenakort 
 
microscopy 
ERG  
 
Dierks et al.  
2005[52] 
IVT rabbit  
eye fundus  
Histology 
4 mg whole 
Kenacort or 
w/o vehicles 
Vehicles 
alone   
7 days Slit lamp 
optical microscopy 
ERG 
No toxicity 
 
Kai et al.   
2006[53] 
IVT rabbit 
intraocular 
pressure 
Histology 
4 or 25 mg 
whole 
Kenacort or 
w/o vehicle  
2 months optical and electonic 
microscopy 
ERG  
Increase in intraocular pressure 
Decrease of ERG 
Toxicity of vehicle but not TA 
 
deKozak et 
al.  
2006[54] 
Subretinal injection 
rabbit 
Histology 
2 mg 
Kenacort w/o 
vehicle 
3 months optical and electonic 
microscopy 
ERG 
OCT 
Toxic for the RPE and outer rod 
segments of photoreceptors 
Crystals of TA toxic for the retina 
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YU et al.   
2006[55] 
IVT rabbit 
Histology 
0,5, 1, 4, 8 
and 20 mg 
whole 
Kenacort or 
vehicles alone 
 
14 days optical and electonic 
microscopy 
ERG  
Toxic for the RPE and outer rod 
segments of photoreceptors above 4mg 
vehicles not toxics  
 
Morrison et 
al. 2006[56] 
IVT rabbit 
Histology 
0.022,0.073, 
0.222  and 
0.733% in 
benzyl alcool 
14 days optical and electonic 
microscopy 
ERG 
Toxic for the RPE and outer rod 
segments of photoreceptors above 
0.073 
 
Lang et al.  
2007[57] 
IVT rabbit  
eye fundus  
Histology 
4 mg whole 
Kenacort or 
vehicles alone 
 
6 weeks optical microscopy 
ERG 
Retinal toxicity due to vehicles 
 
Albini et al.  
2007[58] 
IVT rabbit 4 mg ken 
complet 
17 weeks optical and electonic 
microscopy 
No toxicity 
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Histology 
ERG 
 
Ruiz-Moreno 
et al. 
2007[59] 
IVT rabbit 
Histologie 
immunohistochimie 
4, 20 whole 
Kenacort 
28 weeks optical and electonic 
microscopy 
ERG 
No toxicity 
 
Macky et al. 
2007[60] 
IVT/œil Lapin 
eye fundus 
Histologie 
0.1 ml 
vehicles of 
Kenacort 
6 weeks optical and electonic 
microscopy 
ERG 
Toxic for all the layers of the retina 
 
Ruiz-Moreno 
et al. 
2007[61] 
IVT rabbit 
Histology 
4, 20 or 30 
mg TA 
Benzyl alcool 
28 days optical and electonic 
microscopy 
ERG 
immunohistochemistry 
No toxicity 
 
Yi et al.    
2008[62] 
IVT horse 
eye fundus  
Histology 
10, 20 or 40 
mg TA 
7 or 21 
days 
Biomicroscope 
ERG 
slit lamp 
No toxicity 
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